<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26782">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01957215</url>
  </required_header>
  <id_info>
    <org_study_id>RH01778</org_study_id>
    <nct_id>NCT01957215</nct_id>
  </id_info>
  <brief_title>Efficacy of Topical Indomethacin Patch Over Placebo in Ankle Sprain Pain Relief</brief_title>
  <official_title>A Clinical Study to Assess the Efficacy of Pain Relief of Topical Indomethacin Patch Over Placebo in Ankle Sprain Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rundo International Pharmaceutical Research &amp; Development Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the efficacy of the Indomethacin patch in pain relief of ankle
      sprain in adult patients, compared to a placebo patch
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) which reduces pain, fever,
      stiffness and swelling in acute skeletal musculature injuries involving joints. However,
      oral Indomethacin formulations predisposes for some systemic side effects. To avoid the
      systemic side effects of oral Indomethacin, a topical Indomethacin formulations have been
      developed and approved in some countries as an Over the counter product. Present study is to
      investigate the efficacy of the Indomethacin patch in pain relief of ankle sprain in adult
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sum of Pain Intensity Difference (SPID)</measure>
    <time_frame>From treatment Day 1 to Day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessing efficacy of Indomethacin patch in comparison with placebo patch measured by SPID for pain on movement during the 48 hour time interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Relief Score (PRS)</measure>
    <time_frame>PRS to be assessed Day 1-end of study</time_frame>
    <safety_issue>No</safety_issue>
    <description>PRS to be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical Rating Scale (NRS) for pain</measure>
    <time_frame>NRS on movement Day 1-end of study</time_frame>
    <safety_issue>No</safety_issue>
    <description>NRS for pain on movement (walking 5 steps on flat surface) to be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NRS at rest</measure>
    <time_frame>NRS at rest Day1-Day7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measuring the mean changes from baseline of NRS at rest twice daily (in the morning and afternoon) from treatment day 1 to day 7 between treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of pain relief</measure>
    <time_frame>Day 1-2 ,Day 1-3, Day 1-7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to reach PRS=1; &quot;A little or perceptible pain relief&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPID</measure>
    <time_frame>Day 1-2 ,Day 1-3, Day 1-7</time_frame>
    <safety_issue>No</safety_issue>
    <description>SPID (1-2days), SPID (1-7days) to be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Intensity Difference and Pain Relief (SPRID)</measure>
    <time_frame>Day 1-2 ,Day 1-3, Day 1-7</time_frame>
    <safety_issue>No</safety_issue>
    <description>SPRID to be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Pain Relief (TOTPAR)</measure>
    <time_frame>Day 1-2 ,Day 1-3, Day 1-7</time_frame>
    <safety_issue>No</safety_issue>
    <description>TOTPAR at treatment 1 to 2, 1 to 3, and 1 to 7 days time period between treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to rescue medication</measure>
    <time_frame>Day 1 to Day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rescue medication use to be monitored</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global  Assessment</measure>
    <time_frame>End of study</time_frame>
    <safety_issue>No</safety_issue>
    <description>Global Assessment to be accessed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Ankle Sprain</condition>
  <arm_group>
    <arm_group_label>Indomethacin patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indomethacin patch to be applied on the sprained ankle twice a day (BID).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo patch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo patch to be applied on the sprained ankle BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>Topical indomethacin</description>
    <arm_group_label>Indomethacin patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo patch</description>
    <arm_group_label>Placebo patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant with Grade I or Grade II acute sprain of the lateral ankle within 24
             hours before screening visit

          -  Participant with self-assessed pain intensity score after movement (5 steps) at the
             site of the ankle sprain that is &gt;= 5 as measured on a 0-10 NRS rating.

          -  Participant with a peri-malleolar edema (sub-malleolar perimeter difference of &gt;=20mm
             between injured and uninjured ankle)

        Exclusion Criteria:

          -  Known or suspected intolerance or hypersensitivity to the study materials (or closely
             related compounds) or any of their stated ingredients.

          -  Participant who had medication that could interfere with the subject's perception of
             pain since experiencing ankle sprain.

          -  Pregnancy , Breast Feeding and  Substance Abuse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changzhou NO.2 People?s Hospital</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <zip>213003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Luwan Branch</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shanghai Xuhui Centre Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shanghai Tenth People?s Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shanghai First People?s Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201620</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shanghai Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>info@GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>October 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sprains and Strains</mesh_term>
    <mesh_term>Ankle Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
